AB1601 topline results – Phase 2 study of ABvac40 in patients with amnestic mild cognitive impairment (a‐MCI) or very mild Alzheimer’s Disease (Vm‐AD).

Immunotherapy against amyloid β (Aβ) has emerged as a promising treatment option for Alzheimer’s disease (AD). Araclon‐Biotech is developing an active vaccine against Aβ40 peptide, one of the most abundant peptides in senile plaques and the dominant peptide in vascular deposits, that has been associated with earlier onset of dementia. The immunogen peptide of ABvac40 (Aβx‐40) does not contain the epitope recognized by T cells whose activation was considered the primary cause of aseptic meningoencephalitis. In Phase‐1 (NCT03113812), ABvac40 generated a long‐lasting antibody response after only three‐monthly‐immunizations.